Table 2. Clinical outcomes of patients with stages 3–4 CKD, stratified by Hb and HbA1c quartiles.
| All | Hemoglobin < 10 g/dl | P | Hemoglobin ≥ 10 g/dl | P | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HbA1c quartiles | HbA1c quartiles | ||||||||||
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | ||||
| HbA1c (%) | < 6.4 | 6.4–7.2 | 7.2–8.3 | ≥ 8.3 | < 6.4 | 6.4–7.2 | 7.2–8.3 | ≥ 8.3 | |||
| No. of patients | 1558 | 136 | 90 | 91 | 94 | 256 | 282 | 322 | 287 | ||
| Follow-up days | 1029 (607–1642) |
837 (532–1597) |
875 (520–1512) |
962 (507–1551) |
1025 (554–1765) | 0.595 | 1028 (637–1654) |
1061 (587–1633) |
1051 (581–1695) |
1171 (763–1654) |
0.216 |
| Annual eGFR decline (ml/min/1.73 m2/year) | -3.0 (-7.4 to 0.1) |
-5.4 (-9.4 to -1.6) |
-5.1 (-10.3 to -0.9) |
-5.8 (-13.2 to -1.6) |
-5.0 (-10.2 to -1.0) |
0.767 | -1.5 (-4.5 to 0.7) |
-1.3 (-4.4 to 1.4) |
-2.4 (-6.4 to 0.0) |
-4.0 (-9.6 to -0.4) |
<0.001 |
| Rapid eGFR decline a | 563 (36.1%) | 72 (52.9%) | 45 (50.0%) | 48 (52.7%) | 47 (50.0%) | 0.953 | 60 (23.4%) | 65 (23.0%) | 98 (30.4%) | 128 (44.6%) | <0.001 |
| ESRD | 312 (20.0%) | 44 (32.4%) | 27 (30.0%) | 36 (39.6%) | 25 (26.6%) | <0.001 | 32 (12.5%) | 25 (8.9%) | 48 (14.9%) | 75 (26.1%) | <0.001 |
| All-cause mortality | 271 (17.4%) | 33 (24.3%) | 30 (33.3%) | 26 (28.6%) | 21 (22.3%) | 0.320 | 23 (9.0%) | 38 (13.5%) | 42 (13.0%) | 58 (20.2%) | 0.002 |
| CV event + all-cause mortality | 390 (25.0%) | 48 (39.3%) | 35 (38.9%) | 36 (39.6%) | 31 (33.0%) | 0.653 | 43 (16.8%) | 46 (16.3%) | 59 (18.4%) | 92 (32.1%) | <0.001 |
Abbreviations: ESRD, end-stage renal disease; CV, cardiovascular.
a Annual eGFR decline more than −5 mL/min/1.73 m2/year